Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Evaxion Biotech ( (EVAX) ) has shared an update.
On November 3, 2025, Evaxion A/S announced the expansion of its R&D pipeline with the introduction of EVX-04, a new AI-designed precision cancer vaccine candidate. EVX-04 targets non-conventional ERV tumor antigens and is designed as a therapeutic vaccine for acute myeloid leukemia. The vaccine, which induces strong T-cell responses, will be presented at the American Society of Hematology Annual Meeting in December, highlighting its potential to improve outcomes for patients who do not respond to conventional immunotherapies.
The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall score is driven by strong technical indicators and positive developments from the earnings call, including R&D progress and financial stability. However, financial performance remains a concern due to ongoing losses and reliance on debt, impacting the valuation negatively.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion is a pioneering TechBio company based in Denmark, specializing in developing AI-Immunology™ powered vaccines. The company leverages its proprietary AI platform to create novel immunotherapies for cancer, bacterial diseases, and viral infections, with a focus on personalized vaccines and addressing high unmet medical needs.
Average Trading Volume: 1,587,605
Technical Sentiment Signal: Sell
Current Market Cap: $36.32M
For detailed information about EVAX stock, go to TipRanks’ Stock Analysis page.